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Abstract
 
The marginal zone of the spleen is a precisely ordered region that contains specialized subsets of
B lymphocytes and macrophages. Disruption of the negative signaling inositol phosphatase,
SH2-containing inositol-5-phosphatase 1 (SHIP), results in the loss of marginal zone B cells
(MZBs) with reorganization of marginal zone macrophages (MZMOs) to the red pulp of the
spleen. This primary macrophage defect, as revealed by selectively depleting SHIP in myeloid
cells shows that MZMOs are specifically required for the retention of MZBs. The MZMO
phenotype was reverted in SHIP/Bruton’s tyrosine kinase (Btk) double knockout mice, thus
identifying the Btk activating pathway as an essential component being regulated by SHIP.
Furthermore, we identified a direct interaction between the MARCO scavenger receptor on
MZMOs and MZBs. Activation or disruption of this interaction results in MZB migration to
the follicle. The migration of the MZMOs was further studied after the response to 
 
Staphylococcus
aureus
 
, which induced MZMOs to move into the red pulp while MZBs migrated into the
follicular zone. The marginal zone is therefore a dynamic structure in which retention and
trafficking of B cells requires specific macrophage–B cell interactions.
Key words: SHIP • Btk • MARCO • migration • 
 
Staphylococcus aureus
 
Introduction
 
Blood-borne pathogens first encounter the adaptive immune
system in the marginal zone region of the spleen where the
convergence of innate and adaptive immune mechanisms
insures an early and effective response to pathogen antigens
(1, 2). Both thymic-independent and -dependent responses
are elicited in response to infection (1, 3). The thymic-
independent response involves the targeting and activation
of marginal zone B cells (MZBs)
 
* 
 
through their interaction
with the repetitive antigenic determinants of pathogens
with complement and B cell antigen receptors (4, 5). In
contrast, the thymic-dependent Ab response is driven by
the interaction and reciprocal stimulation of APCs, T lym-
phocytes, and B cells. The organization of the splenic white
pulp nodule into discrete zones enriched for either B cells,
T cells, or APCs provide a spatial microenvironment that
facilitates an efficient interaction of pathogens with the var-
ious cellular populations required for insuring an efficient
immune response (6–8). Antigen presentation and stimula-
tion of T and B cells ultimately results in the formation of
germinal centers, high affinity neutralizing Abs, and mem-
ory cells. Recent reports have begun to define the cellular
components and molecular signals that are necessary to es-
tablish the marginal zone. B cell intrinsic pathways have
been described involving specific chemokines and their re-
ceptors, molecules involved in B cell activation, as well as
adhesion molecules and their ligands (9, 10). Apart from
the MZB, the other predominant cell of the marginal zone
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Abbreviations used in this paper:
 
 Btk, Bruton’s tyrosine kinase; ES, em-
bryonic stem; MZB, marginal zone B cell; MZMO, marginal zone mac-
rophage; SHIP, SH2-containing inositol-5-phosphatase 1.T
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is the marginal zone macrophage (MZMO), which is dis-
tinct from the metallophilic macrophage, defined by the
marker MOMA-1, located at the border of the marginal
and follicular zone (11). The MZMO is defined by its loca-
tion, interspersed in several layers within the marginal
zone, and by its expression of the markers MARCO and
ER-TR9 (12, 13). The former molecule is a scavenger re-
ceptor belonging structurally to the class A receptor family
whereas the latter is identical to the C-type lectin SIGN-
RI (14–17). MARCO has been shown to bind a range of
microbial Ags including 
 
Staphylococcus aureus
 
 and 
 
Escherichia
coli
 
 whereas SIGN-RI is the predominant receptor for up-
take of polysaccharide dextran by MZMOs. Even though
both MZBs and MZMOs are implicated in both thymus-
dependent and -independent immune responses, the exact
roles of the two cell types in initiation of the response to
blood-borne pathogens is not known. We now define a
unique role for the MZMO in regulation of MZB reten-
tion and activation and show that movement of this subset
of macrophages to the red pulp of the spleen involves sig-
naling via SH2-containing inositol-5-phosphatase 1 (SHIP)
and Bruton’s tyrosine kinase (Btk). In addition, we show a
direct interaction between MZMOs and MZBs via the
MARCO receptor on MZMOs and a ligand on MZBs.
 
Materials and Methods
 
Mice.
 
C57BL/6 mice obtained from The Jackson Laboratory
were used as WT mice and controls unless otherwise stated.
Founders of SHIP-deficient mice were provided by G. Krystal
(Terry Fox Laboratory, BC Cancer Agency, Vancouver, Canada;
reference 18) and Btk-deficient mice were purchased from The
Jackson Laboratory. Op/op mice were provided by J. Pollard
(Albert Einstein College of Medicine, New York, NY) and
LysMCre transgenic mice (19) were provided by I. Forster
(Technical University of Munich, Germany). Abs and bacteria
was injected i.v. in the tail vein and all experiments involving
mice were performed in accordance with National Institutes of
Health (NIH) guidelines. All mice were maintained under spe-
cific pathogen-free conditions at The Rockefeller University.
 
Antibodies and Reagents.
 
For histological examination 6-
 
 
 
M
frozen sections were stained, and for FACS
 
® 
 
analysis erythrocyte-
depleted spleen cells were used. Macrophages were detected us-
ing MOMA-1, MARCO Abs from Serotec, and ER-TR9 from
Accurate Chemical & Scientific Corp. Abs to CD1d, B220,
CD19, CD21/CD35 (CRI/II), CD23, MAC-1, anti–rat alkaline
phosphatase, and anti–rabbit horseradish peroxidase were from
BD Biosciences. Secondary Abs for immunohistochemistry, anti-
biotin, anti-FITC F(ab
 
 
 
) horseradish peroxidase, or alkaline phos-
phatase were from DakoCytomation and rabbit anti–SHIP used
for Western blot was from Upstate Biotechnology. Vector Blue
Alkaline Phosphatase Substrate from Vector Laboratories and
DAB peroxidase substrate from Sigma-Aldrich were used for de-
velopment of immunohistochemistry stains. Soluble MARCO
receptor was provided by T. Pikkarainen (The Karolinska Insti-
tute, Stockholm, Sweden; reference 20) and was biotinylated
using the EZ-Link™
 
 
 
kit from Pierce Chemical Co. The bio-
tinylated soluble MARCO was detected using Streptavidin-
CyChrome™ from BD Biosciences. 
 
S. aureus
 
 fluorescent biopar-
ticles were purchased from Molecular Probes, Inc. and MACS
anti-FITC and anti-biotin beads were from Miltenyi Biotec.
Cl
 
2
 
MDP (or clodronate) and PBS liposomes were provided by
Roche Diagnostics.
 
Conditional Targeting of SHIP.
 
Floxed SHIP mice were cre-
ated by insertion of loxP sites flanking the 10th
 
 
 
and 11th
 
 
 
exons
(see Fig. 2 a) of the SHIP gene. The targeting vector was intro-
duced into embryonic stem (ES) cells by electroporation and
clones were selected with neomycin and ganciclovir and verified
by Southern blot and PCR. Properly integrated ES clones were
transiently transfected with a Cre-expressing plasmid. Clones
were subsequently selected for a conditional floxed allele (SHIP
 
flox
 
)
or null allele (SHIP
 
null
 
) using Southern blot and PCR. Appro-
priate ES clones were then injected into blastocysts to generate
chimeric mice. The chimeric mice were then bred with C57BL/6
mice to achieve germline transmission. These mice were subse-
quently crossed with mice expressing Cre in the myeloid com-
partment (LysMcre; reference 19) to generate Cre
 
 
 
/null/flox
mice. Mice were screened for respective genotype by PCR and
SHIP protein expression using Western blot (21) on equal num-
bers of spleen cells purified by MACS (Miltenyi Biotec) sorting
Figure 1. SHIP-deficient mice lack MZBs and MZMOs are displaced
to the red pulp. (a) FACS® profiles of single cell suspensions from the
spleen of SHIP-heterozygous (SHIP / ) and -deficient (SHIP / ) mice.
MZBs were measured as the CD19 , CRIhigh, and CD23low population.
The numbers shown represent percent of CD19  cells for the depicted
gates as an average of five mice. Numbers for the follicular B cells are
shown for comparison. (b) Representative immunohistochemical analysis
of above listed mice. At least four serial sections from each mouse were
stained for MOMA-1   (blue, top) metallophilic macrophages or
MARCO  MZMOs (blue, bottom). Sections were also stained for B220
(brown) to show the positioning of the follicle.  10.T
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according to protocol from the manufacturer. Relative expression
of SHIP in macrophage and B cell populations (comparing wt/
null with flox/null/cre) were estimated using Alpha imager soft-
ware from Alpha Innotech Corp.
 
Results and Discussion
 
Mice deficient in the inhibitory signaling molecule SHIP
display pleiotropic defects in macrophages, NK cells, and
lymphocytes (18, 22). A prominent feature of these mice is
their splenomegaly resulting from dysregulation of myeloid
proliferation. As seen in Fig. 1, SHIP-deficient mice also
display a specific defect in the organization of the splenic
follicle with the loss of MZBs measured as the CD21
 
high
 
/
CD23
 
low 
 
population in FACS
 
® 
 
and in sections as the B220
 
 
 
cells localizing peripherally to the MOMA-1
 
  
 
cells (Fig. 1,
a and b). In the SHIP-deficient mice the MARCO
 
 
 
MZMO cells are no longer organized within the marginal
zone and adjacent to the MOMA-1 macrophages but are
redistributed to the red pulp, whereas MOMA-1
 
  
 
metallo-
phils remain unaffected (Fig. 1 b). Because SHIP is ex-
pressed in most hematopoietic cells, including lymphoid
and myeloid subsets, we determined if this marginal zone
phenotype in SHIP-deficient mice was the result of pri-
mary macrophage dysregulation. A conditional disruption
of SHIP was generated in which macrophages displayed an
approximate 
 
 
 
90% reduction in SHIP expression whereas
B cell expression was reduced by 
 
 
 
10% (Fig. 2, a and b).
This is consistent with the expression patterns of Cre re-
combinase, driven by the lysosyme promoter used (19).
The mice developed a splenomegaly at 
 
 
 
5 wk of age (Fig.
2 b), similar to that of complete SHIP deletion, thus impli-
cating a primary macrophage defect as the cause for sple-
nomegaly in SHIP
 
    
 
mice (18). In addition, the mice dis-
played essentially the same marginal zone phenotype with
significantly reduced MZBs as defined by flow cytometry
and reorganization of the MZMOs as observed by histo-
logical staining (Fig. 2 c). To confirm that the SHIP phe-
notype is B cell nonautonomous and that SHIP-deficient B
cells can give rise to MZB populations when WT MZMOs
are available, we produced BM chimeras using SHIP-defi-
cient BM combined with WT BM and injected these cells
into irradiated WT recipients. In the resulting chimeric
mice the SHIP-deficient and WT BMs contributed equally
to the MZB population (unpublished data).
In B cell lines it has been shown that SHIP functions as a
negative regulator of cellular activation by regulating the
association of the positive signaling kinase Btk with the
membrane, thus raising the threshold required for stimula-
tion (23). It does so by hydrolyzing PIP
 
3
 
, the substrate for
Btk association with the membrane, thereby reducing the
ability of Btk to become membrane associated and acti-
vated (24). Because both SHIP and Btk are expressed in
Figure 2. Conditional targeting of SHIP in macro-
phages results in MZMO displacement and reduced
numbers of MZBs. (a) A targeting construct covering
exons 10 to 13 of SHIP, from EcoRI (E) to HindIII
(H), was made. Boxes represent exons and triangles
represent loxP sites flanking exons 10 to 11 and a neo-
mycin resistance gene (neo). Properly integrated ES
cell clones were transiently transfected with Cre re-
combinase to create conditional floxed (SHIPflox) or
null (SHIPnull) clones. These cells were subsequently
used to create floxed (flox) and null mice, which were
crossed to mice expressing Cre from a macrophage-
specific lysosomal promoter (cre). (b) Western blot
analysis of MAC1  and CD19  spleen cells (SPC) from
WT, WT/null, null/null, LysM floxed (flox/null/cre),
and relative spleen size of 6-wk-old WT/null and flox/
null/cre SHIP mice. (c) FACS® and histological pro-
files of single cell suspensions from the spleen of the
conditionally targeted SHIP KO mice. MZBs were
measured as the CD19 , CRIhigh, and CD23low popula-
tion. The numbers shown represent percent of CD19 
cells for the depicted gates as an average of five mice
and the numbers for the follicular B cells are shown for
comparison. For representative immunohistochemical
analysis, at least four serial sections were stained for
MOMA-1  (blue, top) metallophilic macrophages or
MARCO  MZMOs (blue, bottom). Sections were
also stained for B220 (brown) to show the positioning
of the follicle. Refer to Fig. 1 for SHIP    and SHIP   
profiles.  10.T
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macrophages and a link between these molecules had been
suggested, we reasoned that the myeloid proliferation and
MZMO phenotype leading to the loss of MZBs might be
the result of inappropriate activation of Btk in macrophages
of SHIP-deficient animals (25, 26). Disruption of Btk in
macrophages may thus be sufficient to restore normal sig-
naling thresholds in SHIP-deficient mice. Combining the
SHIP deficiency with a Btk deficiency resulted in the res-
toration of both the normal marginal zone structure (Fig. 3
a) and spleen size (Fig. 3 b) indicating that Btk is an impor-
tant target of SHIP in myeloid cells in vivo. Similarly, Btk
deficiency counteracted the over responsiveness of myeloid
progenitors to GM-CSF and M-CSF in SHIP-deficient
mice (unpublished data). Both the dysregulation of myeloid
proliferation and follicular architecture likely result from
enhanced signaling through the Btk pathway in myeloid
cells. Reversion of the MZB and myeloid phenotypes in
SHIP
 
    
 
mice by deletion of Btk suggests that Btk is the
dominant Tec family member regulated by SHIP in these
cells. The observation that other members of the family are
expressed in macrophages and have been shown to be able
to substitute for Btk both in vivo and in KO mice indicates
a surprising degree of specificity to the SHIP inhibitory
pathway (27–29).
These results suggested that MZMOs might be critical to
the organization of the white pulp nodule and localization
of MZBs in this structure. To test this directly we exploited
the observation that MZMOs can be ablated by their pref-
erential ingestion of macrophage-depleting liposomes (30).
At a low concentration of these liposomes we could see
preferential depletion of MARCO
 
  
 
MZMOs as opposed
to the adjacent MOMA-1 macrophages (Fig. 4). Other
phagocytic cells in the spleen, such as red pulp macrophages
and dendritic cells were largely unaffected by this treatment
Figure 3. SHIP and Btk interact in
myeloid proliferation and activation.
(a) FACS® and histological profiles of
single cell suspensions from the spleen
of SHIP and Btk double KO mice
(SHIP / /Btk ). MZBs were mea-
sured as the CD19 , CRIhigh, and
CD23low  population. The numbers
shown represent percent of CD19 
cells for the depicted gates as an aver-
age of four mice and the numbers for
the follicular B cells are shown for
comparison. For representative immu-
nohistochemical analysis, at least four
serial sections from were stained for
MOMA-1  (blue, top) metallophilic
macrophages or MARCO  MZMOs
(blue, bottom). Sections were also
stained for B220 (brown) to show the
positioning of the follicle.  10. (b)
Relative spleen size of 5-wk-old het-
erozygous KO or double KO mice.
Figure 4. MARCO   MZMOs are re-
quired for retention of MZBs. Representa-
tive immunohistochemical analysis and
FACS® profiles of spleens from at least four
WT mice treated with liposomes or un-
treated op/op mice. WT mice were injected
i.v. with 100  l PBS containing liposomes
or with liposomes containing clodronate at a
1:24 dilution where MZMOs were prefer-
entially depleted. 48 h later serial spleen
sections were stained for MOMA-1 
(blue,  top) metallophilic macrophages or
MARCO   (blue, middle) MZMOs. The
sections were also stained for B220 (brown)
to see the positioning of these populations in
relation to the B cell follicle.  10. Spleen
cells were analyzed by FACS® analysis for
detection of MZBs as measured by the
CD19 , CRIhigh, and CD23low population.
Numbers shown are the average percent-
positive cells of four mice. Similar profiles
are shown for untreated op/op mice (right).
Data shown are representative of three inde-
pendent experiments.T
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(not depicted). When MZMOs were depleted in this fash-
ion, we observe a specific reduction in the MZBs by both
flow cytometry and histological staining. In contrast,
MOMA-1 macrophages are specifically absent in the CSF-
1–deficient strain 
 
op/op
 
 but these mice retain MARCO
 
 
 
/
ER-TR9
 
  
 
MZMOs (31, 32). The absence of the MOMA-
1
 
  
 
cells and the ER-TR9 marker did not result in reduc-
tion in MZBs, but rather, an expansion of these cells is ob-
served, indicating that the macrophage population that is
required for MZB retention are the MARCO
 
  
 
MZMOs.
The identity of the retention signal expressed by
MARCO
 
  
 
MZMO cells was next determined by investi-
gating the role of specific surface receptors on the MZMO
in maintaining the marginal zone structure. The MARCO
receptor, in addition to binding to bacteria (33), contains
an SRCR domain that has been implicated in binding to
CD19
 
  
 
lymphocytes (34, 35). To determine if MARCO
itself is capable of binding to MZBs, we expressed the ex-
tracellular domains of MARCO as a soluble molecule (20)
and used it to stain splenic populations (Fig. 5). Three pop-
ulations of cells were distinguished by flow cytometry
when stained with CD21 and CD23. Maximal binding to
soluble MARCO was observed for the MZBs (CD21
 
hi
 
CD23
 
low
 
), whereas the follicular B cells (CD21
 
low 
 
CD23
 
hi
 
)
displayed reduced binding. None of the other splenic pop-
ulations (T cells, macrophages, or dendritic cells) were ca-
pable of binding to soluble MARCO. This binding was
specific for the MARCO SRCR domain, as determined
by the ability of a monoclonal Ab to this domain (ED31;
reference 33) to block the binding of soluble MARCO to
MZBs. When the MARCO-specific Ab was injected i.v.
to WT mice it resulted in disruption of the marginal zone
structure in which MZBs, identified by CD1d staining,
were found in the follicular region whereas MZMOs,
identified by ER-TR9 staining, were retained in the
marginal zone (Fig. 6). These results suggest that a direct
interaction between MZMO and MZBs is mediated by
Figure 5. Soluble MARCO receptor (sMARCO) binds preferentially
to MZBs. Representative FACS® analysis of spleen cells from WT mice
stained with CRI, CD23, and biotinylated sMARCO. Binding of
sMARCO to different spleen cell populations was based on gates set on
the CRI versus CD23 stain. red, MZBs; blue, follicular B cells; black,
non-B cells. The histogram (bottom) shows the mean fluorescence index
(MFI) and SD (n   5) for the different populations as well as the avidin
(Av) control and block using the MARCO-specific ED31 Ab. Data
shown are representative of three independent experiments.
Figure 6. In vivo disruption of MARCO and MZB interactions leads
to MZB migration to the follicle. WT mice were given 100  g control
rat IgG or anti-MARCO (ED31) IgG i.v. 3 h later the mice were killed
and the spleens were stained for macrophage and B cell populations. Rep-
resentative stains of serial sections from at least four different mice are
shown. MZMOs were detected with anti-MARCO (blue, top) or
ER-TR9 (blue, middle) antibodies whereas metallophilic macrophages
were stained with MOMA-1 (brown, bottom). B220  B cells (brown)
were stained for positioning of the follicle and MZBs as the CD1high (blue,
bottom) population.  10. Part of the spleen was used for flow cytometric
analysis to determine the CD19 , CRIhigh, and CD23low populations.
Numbers shown are the average of four mice. The percent of CD19 
cells for either MZBs or follicular B cells is shown for comparison. Data
shown are representative of two independent experiments.T
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MARCO–MZB binding, through a MARCO ligand ex-
pressed on these B cells, and provides a mechanism for the
retention of MZBs by MARCO-expressing MZMO cells.
Perturbation of this interaction either by disruption of ad-
hesion and/or induction of macrophage activation by
MARCO cross-linking results in the appearance of cells
expressing a MZB surface phenotype in the follicular zone.
To address the relevance of the MARCO
 
  
 
MZMO and
its retention of MZBs to its contribution to the develop-
ment of an immune response to pathogens, we injected
mice i.v. with rhodamine-conjugated 
 
S. aureus
 
, which is a
known ligand for the MARCO receptor (12). Within 30
min of injection bacteria were visualized exclusively bound
to the MZMO cells, a role consistent with the phagocytic
property of these scavenger receptor–expressing cells (Fig.
7). 18 h after injection the microbes and the MZMO were
found to have comigrated into the red pulp and cells with a
MZB phenotype (CD1d
 
high
 
) were mostly found in the fol-
licular region. These results are consistent with a model in
which interaction of 
 
S. aureus
 
 with MARCO on MZMOs
results in their migration into the red pulp and the con-
comitant migration of MZBs into the follicular region as
has been reported for LPS and 
 
E. coli
 
 (8, 9). The deletion of
the inhibitory signaling molecule SHIP results in a similar
MZMO migration response, suggesting that MZMO acti-
vation can trigger migration into the red pulp. We presume
that the likely explanation for the migration seen in re-
sponse to 
 
S. aureus
 
 ingestion is the activation of MZMOs
by their encounter with these bacteria as has been described
(36, 37). A similar result was observed for E. coli suggesting
a more general migratory response by MZMO cells to mi-
crobial challenge (unpublished data). The migratory re-
sponse of the MZMO, carrying Ag to the red pulp, could
simply be a method of clearance of particulate Ags or alter-
natively MZMOs could function as Ag transporters/pre-
senters and supporters of plasmablast formation shown to
take place in the red pulp (Fig. 8; references 38–40). This
has previously been reported to be a function of dendritic
cells in the T/B cell border of the follicle and by macro-
phages supporting B1 B cells in the peritoneum (10). Inter-
estingly, Kang et al. (14) recently showed that phagosomes
in MZMOs, after uptake of dextran polysaccarides via
SIGN-RI did not stain positive for the endosomal markers
LAMP-1 and transferrin. This suggests that Ags taken up
Figure 7. S. aureus induce
MZMO movement and displace-
ment of MZBs. WT mice were in-
jected i.v. with 250  g heat-killed
and rhodamine-conjugated S. aureus
in PBS. 0.5 or 18 h later the mice
were killed and the spleens were sec-
tioned and stained. Representative
stains from at least four mice are
shown. MARCO   MZMOs (left)
are stained blue and B220  B cells
are stained brown. The middle
shows the same stains as in the left,
merged with the fluorescent stain of
S. aureus. The right shows stains for
the CD1high MZB population (blue)
and MOMA-1  metallophilic mac-
rophages (brown).  10. The data
shown are representative of two in-
dependent experiments.
Figure 8. Proposed model for interactions between MZMO and MZB
and the response of these cells to blood-borne pathogens. In the marginal
zone (MZ), MZBs interact with the MZMO via the MARCO receptor
(a) and with stromal elements via the ICAM/VCAM and their respective
ligands LFA-1 and  4 1 (b). Upon phagocytosis of particulate Ags, the
MARCO  MZMOs migrate to the red pulp (c) and the majority of the
MZBs migrate to the follicle where they interact with cells such as den-
dritic and follicular dendritic (d, DC and FDC). In the early response to T
cell–independent Ags, the MZB also has the capacity to migrate to the
red pulp to take part in plasma cell formation (e), where a possible inter-
action with MZMOs and MZBs may take place.T
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by MZMOs may not necessarily take the route of normal
phagosome maturation (41) resulting in destruction or Ag
presentation and thus could provide a mechanism to trans-
port intact Ag to the red pulp by MZMOs.
These results suggest that the interaction of MZMO cells
with MZBs is required to maintain the marginal zone
structure and that this association is perturbed upon
MZMO binding and activation by microbial pathogens. It
is likely that the MZBs migrate into the follicular zone in
response to CXCL13 (9) in the absence of retention signals
from the MARCO  MZMO. This pathway is likely to be
independent of the integrin pathway involving stromal
VCAM/ICAM and B cell LFA-1/ 4 1 because disruption
of that pathway with antibodies to LFA-1 and  4 1 results
in the release of MZBs to the blood stream (9), not their
migration into the follicle, in contrast to the results pre-
sented here (Fig. 8). In addition, we see no effect on the lo-
calization of MZMO cells using antibodies to the stromal
integrins, nor do we observe effects on their ligand expres-
sion when MZMO cells are triggered to migrate (unpub-
lished data). These pathways are thus likely to serve differ-
ent functions in the organization of the marginal zone,
with the MZMO pathway specific for the antimicrobial re-
sponse, leading to internalization of the organism and traf-
ficking of B cells into the follicular zone to propagate the
immune responses. MZBs have the capacity to bind
polysaccharide Ags through complement-mediated path-
ways and transport these to the follicular area of the spleen
(6, 8, 42). The events we have described appear to be an-
other mechanism for delivery of MZBs and Ag to the T
cell–rich follicular region. MZBs have mostly been impli-
cated in the response to T cell–independent Ags, however,
they are also capable of presenting Ags (43) and may thus
be important both for the T cell–dependent and –indepen-
dent phase of the earliest defense against a pathogen.
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